Loading...

FATE FATE THERAPEUTICS INC Management Changes 8-K Filing

FT T

FT

FATE THERAPEUTICS INC

(FATE)

2025 8-K

Financial Results Report

Clinical Trial Update

Management Changes

Financial Statements

Financial Results

Management Changes

Management Changes

Financial Results

Indemnification Agreement

Financial Results

Board Increase and Appointm...

Amendment Approval

Appointment of CFO

Resignation and Appointment

Financial Results Announcement

Phase 1 Study Results

Equity Offering

Financial Results Announcement

Registration Statement and ...

Earnings Reports

Litigation Update

Earnings Report

Annual Meeting Results

Resignation of CMO

Presentation at Jefferies H...

Earnings Reports

Amendment to Certificate of...

Financial Results Announcement

Termination of Collaboratio...

External Links:

Fate Therapeutics, Inc. reported the resignations of Dr. John D. Mendlein and Dr. Neelufar Mozaffarian from the Board effective October 13, 2025, and appointed Kamal Adawi as the new Chief Financial Officer with an annual salary of $495,000 and performance bonuses.

AI Assistant

FATE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.